Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Galunisertib |
| Trade Name | |
| Synonyms | LY2157299|LY-2157299 |
| Drug Descriptions |
Galunisertib (LY2157299) is a TGFBR1 antagonist, which inhibits downstream signaling and may suppress tumor growth (PMID: 18039567, PMID: 32210440). |
| DrugClasses | TGFBR1 inhibitor 16 |
| CAS Registry Number | 700874-72-2 |
| NCIT ID | C116891 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Abemaciclib + Galunisertib | Abemaciclib Galunisertib | 0 | 1 |
| Capecitabine + Galunisertib | Capecitabine Galunisertib | 0 | 2 |
| Carboplatin + Galunisertib + Paclitaxel | Carboplatin Galunisertib Paclitaxel | 0 | 1 |
| Durvalumab + Galunisertib | Durvalumab Galunisertib | 0 | 1 |
| Fluorouracil + Galunisertib | Fluorouracil Galunisertib | 0 | 1 |
| Galunisertib | Galunisertib | 0 | 6 |
| Galunisertib + Paclitaxel | Galunisertib Paclitaxel | 0 | 1 |
| Galunisertib + Sorafenib | Galunisertib Sorafenib | 0 | 1 |